The purpose of this study is to evaluate the safety and tolerability of escalating doses of ODM-103 when given to healthy male volunteers.

The study is divided into two parts. Part one is a crossover study where healthy volunteers will receive two doses of ODM-103 and one dose of placebo. Part II of the study is a multiple ascending dose parallel group study where healthy volunteers will receive ODM-103 three times daily for seven days. Healthy volunteers taking part in Part II of the study will also receive levo/carbidopa and entacapone four times daily on day 1 and levo/carbidopa in addition to ODM-103 on day 9. The study will also look at the pharmacokinetic(how the body handles the drug) and pharmacodynamics (how the drug affects the body) of ODM-103.

Inclusion Criteria:

• Male subjects aged between 18 and 45 years
• BMI 18-30 kg/m2
• Weight 55-90kg
• Written informed consent
• Good General Health

Exclusion Criteria:

• Vulnerable subjects
• Veins unsuitable for repeated venipuncture
• Evidence of clinically significant cardiovascular, renal, hepatic, hematological, Gi, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disorder
• History of or positive test for drug abuse
• Any condition requiring regular concomitant medication
• Blood donation or significant loss of blood within 3 months prior to screening
• Abnormal 12 lead ECG finding of clinical relevance
• Heart rate (HR) <50bpm or >90bpm after 10 minutes in a supine position
• Systolic blood pressure <90mmHg or >140mmHg after 10 minutes in a supine position
• Diastolic blood pressure <50mmHg or >90mmHg after 10 minutes in a supine position
• Abnormal 24 hour Holter recording of clinical relevance at screening
• Any abnormal laboratory value, vital signs or physical examination causing a health risk to the volunteer